E34.50 Androgen insensitivity syndrome, unspecified

Name of the Condition

• Androgen Insensitivity Syndrome, Unspecified (ICD-10 Code: E34.50)

Summary

Androgen insensitivity syndrome, unspecified, is a genetic condition where individuals with XY chromosomes have reduced or absent response to androgens, leading to impaired male sexual development. The term "unspecified" indicates the condition is documented without further detail on the degree of insensitivity. This results in varying degrees of undermasculinization, which may include ambiguous genitalia, primary amenorrhea, or infertility, requiring clinical and genetic evaluation for diagnosis.

Causes

AIS is caused by mutations in the androgen receptor gene, which disrupts the body’s ability to respond to androgens. These mutations can be inherited or occur spontaneously. The unspecified designation suggests the clinical documentation does not specify whether the insensitivity is partial or complete, or the exact nature of the receptor dysfunction.

Risk Factors

• Genetic mutations in the androgen receptor gene.
• Family history of AIS or related disorders.
• Sporadic mutations in individuals with no family history.

Symptoms

• Ambiguous genitalia at birth (in partial cases).
• Primary amenorrhea (absence of menstruation) in adolescents.
• Infertility or reduced fertility.
• Lack of or sparse body hair (in complete cases).
• Normal breast development (due to estrogen conversion).

Diagnosis

Diagnosis involves clinical evaluation of sexual development, hormone level testing (e.g., elevated testosterone with low dihydrotestosterone), and genetic testing for androgen receptor mutations. Imaging or biopsy may be used to assess gonadal tissue, and karyotyping confirms XY chromosomes. The unspecified code is used when the degree of insensitivity is not documented.

Treatment Options

Treatment focuses on managing symptoms and may include hormone therapy, surgical interventions for ambiguous genitalia or gonadal tissue, and psychological support. Fertility options, such as assisted reproductive technologies, may be considered based on individual circumstances.

Prognosis and Follow-Up

Prognosis depends on the degree of insensitivity and associated complications. Regular follow-up is essential to monitor for gonadal tumors, bone health, and psychosocial well-being. Hormone replacement therapy may be needed to support bone density and secondary sexual characteristics.

Complications

• Increased risk of gonadal tumors (e.g., gonadoblastoma) if gonads are present.
• Osteoporosis due to estrogen deficiency.
• Psychosocial challenges related to gender identity and sexual function.

Lifestyle & Prevention

• Genetic counseling for affected individuals and families.
• Regular medical monitoring to detect early complications.
• Supportive care for psychosocial and reproductive health.

When to Seek Professional Help

Seek medical attention for symptoms like ambiguous genitalia at birth, delayed puberty, or infertility. Prompt evaluation is important for early diagnosis and management of potential complications.

Tips for Medical Coders

Use E34.50 when the clinical documentation specifies androgen insensitivity syndrome but does not provide details on the degree of insensitivity (partial or complete). Ensure the code aligns with the documented absence of further specification. Verify that the diagnosis is supported by clinical findings and does not require a more specific code if details are available.